Fosgonimeton - Misplaced Pages

Chemical compound

Pharmaceutical compound

Fosgonimeton
Legal status

Legal status	Investigational
Identifiers
IUPAC name -3-methyl-1-oxopentan-2-yl]amino]-2-(hexanoylamino)-3-oxopropyl]phenyl] dihydrogen phosphate
CAS Number	2093305-05-4
PubChem CID	156596375
ChemSpider	115009339
UNII	H91OA9858J
KEGG	D12392
ChEMBL	ChEMBL5095419
Chemical and physical data
Formula	C₂₇H₄₅N₄O₈P
Molar mass	584.651 g·mol
3D model (JSmol)	Interactive image
SMILES CCCCCC(=O)N(CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N((C)CC)C(=O)NCCCCCC(=O)N
InChI InChI=1S/C27H45N4O8P/c1-4-6-8-12-24(33)30-22(18-20-13-15-21(16-14-20)39-40(36,37)38)26(34)31-25(19(3)5-2)27(35)29-17-10-7-9-11-23(28)32/h13-16,19,22,25H,4-12,17-18H2,1-3H3,(H2,28,32)(H,29,35)(H,30,33)(H,31,34)(H2,36,37,38)/t19-,22-,25-/m0/s1 Key:MBYDCPOKVKDSFD-JTJYXVOQSA-N

Fosgonimeton is an investigational new drug that is being evaluated to treat neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It is a pro-drug of the active metabolite dihexa. Dihexa in turn binds to the hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met.

References

"Fosgonimeton - Athira Pharma". AdisInsight. Springer Nature Switzerland AG.
Reda SM, Setti SE, Berthiaume AA, Wu W, Taylor RW, Johnston JL, et al. (April 2024). "Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease". Neurotherapeutics. 21 (4): e00350. doi:10.1016/j.neurot.2024.e00350. PMC 11067346. PMID 38599894.

EGF (ErbB1/HER1)	Agonists: Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα) Kinase inhibitors: Afatinib Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab
ErbB2/HER2	Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib Lapatinib Mubritinib Neratinib Tucatinib
ErbB3/HER3	Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies: Duligotumab Patritumab Seribantumab
ErbB4/HER4	Agonists: Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))

FGFR1	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20) Repifermin Selpercatinib Trafermin Velafermin
FGFR2	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22) Palifermin Repifermin Selpercatinib Sprifermin Trafermin Antibodies: Aprutumab Aprutumab ixadotin Kinase inhibitors: Infigratinib
FGFR3	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23)
FGFR4	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8, 9, 19) Trafermin
Unsorted	Agonists: FGF15/19

Others

Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
Trofinetide

GFRα1	Agonists: Glial cell line-derived neurotrophic factor (GDNF) Liatermin Kinase inhibitors: Vandetanib
GFRα2	Agonists: Neurturin (NRTN) Kinase inhibitors: Vandetanib
GFRα3	Agonists: Artemin (ARTN) Kinase inhibitors: Vandetanib
GFRα4	Agonists: Persephin (PSPN) Kinase inhibitors: Vandetanib
Unsorted	Kinase inhibitors: Agerafenib